Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs placebo in severe persistent asthma on oral corticosteroids
2010-020803-63Phase 3Withdrawn
- Sponsor
- AB Science
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in severe asthma and asthma comparing Masitinib 6 mg/kg/day with Placebo (2 arms). Primary endpoint: Asthma exacerbation rate at 36 weeks. Planned start Jul 2010; status: withdrawn.
02
Drugs
masitinib
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2010-020803-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020803-63.